SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

Quants selection for The Clearing Houses on-chain money initiative has fueled attention, with traders tying the institutional-finance news to potential demand for QNT and its limited supply. The community is divided between bullish supply-squeeze expectations and skepticism that the partnership necessarily creates token demand, while sharp swings have prompted both dip-buying and profit-taking.

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Kodiak Sciences Inc

Kodiaks Phase 3 DAYBREAK trial met its primary endpoints for two experimental wet-AMD drugs, with Zenkuda matching Eylea on vision outcomes and showing potential for six-month dosing; traders are celebrating the results and possible path toward an FDA filing. Others question the drugs advantage over newer competitors and warn that the sharp rally may be vulnerable to profit-taking or future financing-related dilution.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

AstraZenecas agreed $2 billion investment in Summit, alongside a clinical-trial collaboration involving ivonescimab, is driving attention. Traders view the deal as strengthening Summits funding and validating its cancer-drug program, while others caution that it is an equity investmentnot a buyoutand does not resolve the drugs FDA or clinical risks.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Michael Burrys shift from a Palantir short to a larger put position, alongside his warning that the AI bubble could burst, is driving discussion. Bulls dismiss the bearish call and point to Palantirs AI growth and recent strength, while bears cite valuation concerns; traders are also watching the stocks choppy moves near resistance.

MongoDB, Inc. engages in the development and provision of a general-purpose database platform. The firm's products include MongoDB Enterprise Advanced, MongoDB Atlas, and Community Server. It also offers professional services including consulting and training. The company was founded by Eliot Horowitz, Dwight A. Merriman, Kevin P. Ryan, and Geir Magnusson Jr. in 2007 and is headquartered in New York, NY.

MongoDB Inc - Ordinary Shares - Class A

MongoDB Inc

MongoDB shares are under pressure after CEO C.J. Desai abruptly left for a senior role at Meta shortly before Investor Day, with former CEO Dev Ittycheria returning as interim chief while the company seeks a permanent successor. Traders are divided between seeing the transition as a source of strategic uncertainty and calling the selloff an overreaction, noting that MongoDB reaffirmed its guidance.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

OCUL is selling off after competitor Kodiak reported positive late-stage results for its wet AMD drug, raising concerns about competition in the market for longer-lasting retinal treatments. Traders debate whether Kodiaks dosing data truly challenges AXPAXLI, with many OCUL holders calling the drop an overreaction and pointing to AXPAXLIs durability and planned NDA filing.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas was selected for the U.S. Armys ALATTIS program to develop ultra-high-voltage silicon-carbide power technology, drawing attention to the award as a validation of its capabilities and potential defense and infrastructure applications. Traders are bullish on the recognition, while others caution that it is a prototype program with undisclosed financial termsnot a production contract or clear near-term revenue sourceand debate whether the initial pop will hold.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

C3.ais fiscal first-quarter results are driving discussion: an adjusted earnings beat and positive free cash flow were offset by sharply lower revenue and a softer revenue outlook. Traders are split between viewing restructuring, higher bookings and founder Thomas Siebels return as signs of a turnaround, and arguing that weak growth and ongoing losses undermine the bull case; some also speculate that high short interest could fuel a squeeze.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

CEO Dave Ricks comments that Lilly may pursue larger acquisitions beyond obesity are driving discussion, with traders viewing the GLP-1 cash flow as funding pipeline diversification. The broader conversation also weighs Lillys growth prospects against its valuation and intensifying competition in obesity drugs.

Himax Technologies, Inc. is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The company's products include display drivers, timing controllers, wafer level optics, video and display technology solutions, liquid crystal over silicon silicon, complementary metal-oxide semiconductor image sensor, and power integrated circuit. Its products used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, car navigation, virtual reality (VR) devices and many other consumer electronics devices. Himax Technologies was founded by Biing Seng Wu and Jordan Wu on June 12, 2001 and is headquartered in Tainan, Taiwan.

Himax Technologies - ADR

Himax Technologies, Inc.

Traders are focused on Himaxs potential role in co-packaged optics (CPO) through its FOCI partnership, with speculation that future AI data-center demand and production ramps could become growth drivers. Bullish long-term views compete with frustration over HIMXs weak, volatile trading and uncertainty about when the opportunity will meaningfully affect results.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Themes ETF Trust - Leverage Shares 2X Long MU Daily ETF

Neutral Sentiment

Adding risk (buying more)

Trimming/taking profits

Rotating into safer assets

Staying the course, no changes

We&#39;re about to enter Q4 - how are you positioning your portfolio for the rest of the year?

Stocktwits

We're about to enter Q4 - how are you positioning your portfolio for the rest of the year?

Current Price	$18.06
Prev Close	$19.12
Open	$18.81
Dividend Yield	N/A
50-Day Moving Average	$16.06
Beta	N/A
Avg. Volume	4,269.11
PE Ratio	N/A

52-Week High	$19.70
52-Week Low	$13.50
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

MUG Fundamentals